Figure 4From: A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteersMethotrexate (MTX) plasma concentration from day 0 to day 4. Five participant provided blood each day, thus each point represents a mean of 5 measurements. IC99 represents MTX concentration that inhibits 99% of parasite growth in vitro.Back to article page